Stoke Therapeutics Q1 net loss $26.4M; STK-001 data supports disease modification

Stoke Therapeutics, Inc.

2024-Q1 EPS reported -$0.57 revenue$4,216,000

Net loss $26.4M ($0.57/share) vs $22.5M ($0.53) YoY; cash $178.6M at March 31, plus $120.3M net from April follow-on offering.
STK-001 data from 81 patients showed durable seizure reductions and cognitive/behavior improvements; plans to discuss registrational study with regulators, update H2 2024.
Revenue from Acadia collaboration $4.2M (down from $5.2M); R&D expenses rose to $22.4M from $19.6M.
Appointed Jason Hoitt as CCO and Tommy Leggett as CFO.
Plans to initiate Phase 1 OSPREY trial for STK-002 in ADOA in 2024; FALCON natural history data presented at ARVO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Stoke Therapeutics, Inc. reported the three months ended March 31, 2024 results: revenue $4.2 million, net income $26.4 million, EPS $0.57 per share.

Period: the three months ended March 31, 2024
Revenue: $4.2 million
Net income: $26.4 million
EPS: $0.57 per share
Result: reported results

Exact text from the filing

Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended March 31, 2024 was $4.2 million, compared to $5.2 million, for the same period in 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.